International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Principal Investigator: Mark J. Abzug, MD
Source: NICHD, NIH - BRS-IMPCT-Q-06-00116-T00
Amount: $2,450/yr
Term: 2006 - 2007
NIH Collaborative Antiviral Study Group: A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril in the Treatment of Neonates with Enterovirus Sepsis Syndrome
Principal Investigator: Mark J. Abzug, MD
Source: NIAID, NIH - N01-A1-30025
Amount: Per patient enrolled
Term: 1999 - ongoing
NIH Collaborative Antiviral Study Group: A Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Oseltamivir for the Treatment of Children <24 Months of Age with Confirmed Influenza Infection
Principal Investigator: Mark J. Abzug, MD
Source: NIAID, NIH - N01-AI-30025
Amount: Per patient enrolled
Term: 2007 - ongoing
NIH Collaborative Antiviral Study Group: Phase 3 Randomized, Placebo-Controlled Blinded Investigation of 6 Weeks vs. 6 Months of Oral Valganciclovir in Infants with Symptomatic Congenital Cytomegalovirus Infection
Principal Investigator: Mark J. Abzug, MD
Source: NIAID, NIH - N01-AI-30025
Amount: Per patient enrolled
Term: 2007 - ongoing
NIH Collaborative Antiviral Study Group: Retrospective Chart Review to Assess the Safety of Oseltamivir Compared to Alternate Antiviral Therapy Administered to Children Less than 12 Months of Age
Principal Investigator: Mark J. Abzug, MD
Source: NIAID, NIH - N01-AI-30025
Amount: $1720
Term: 2006 - 2008
Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme)
Principal Investigator: Kenny Chan, MD
Co-Investigator: Mark J. Abzug, MD
Source: Genentech, Inc.
Amount: Per patient enrolled
Term: 2006 - ongoing
Fever and Neutropenia in Pediatric Oncology Patients: A Randomized, Controlled, Multicenter Study of Outpatient Therapy and Evaluation of Genomic and Proteomic Correlates
Principal Investigator: Sue Lindemulder, MD
Consultant: Mark J. Abzug, MD
Source: St. Baldrick's Foundation Grant
Amount: $18,600/yr
Term: 2006 - 2008
Fever and Neutropenia in Pediatric Oncology Patients: A Randomized, Controlled, Multicenter Study of Outpatient Therapy and Evaluation of Genomic and Proteomic Correlates
Principal Investigator: Sue Lindemulder, MD
Consultant: Mark J. Abzug, MD
Source: Pediatric Clinical Translational Research Center Pilot and Feasibility Program Grant
Amount: $19,880/yr
Term: 2006 - 2008
Hematology Oncology Fellowship Program Grant: Fever and Neutropenia in Pediatric Oncology Patients
Principal Investigator: Sue Lindemulder, MD
Consultant: Mark J. Abzug, MD
Source: Amgen Inc.
Amount: $40,000/yr
Term: 2006 - 2007
Safety of Ciprofloxacin in Pediatric Patients
Principal Investigator: Marsha S. Anderson, MD
Source: Bayer Corporation
Amount: Per patient enrolled
Term: 2001 - 2007
Phase III, Open-Label, Randomized, Multicenter Study to Evaluate Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine Administered with Routine Infant Vaccinations (Infants)
Principal Investigator: Marsha S. Anderson, MD
Co-Principal Investigator: Mary P. Glodé, MD
Source: Novartis AG
Amount: Per patient enrolled
Term: 2007 - 2009
Phase III Randomized, Multicenter Study to Evaluate Lot-to-Lot Consistency of Novartis Meningococcal ACWY Conjugate Vaccine and to Evaluate Safety and Immunogenicity in Adolescents 11-18 Years
Principal Investigator: Marsha S. Anderson, MD
Co-Principal Investigator: Mary P. Glodé, MD
Source: Novartis AG
Amount: Per patient enrolled
Term: 2007 - 2009
Region VIII Center for Excellence for Biodefense and Emerging Infectious Diseases: Education and Outreach Subproject
Principal Investigator (Subproject): Marsha S. Anderson, MD
Co-Principal Investigator: Ann-Christine Nyquist, MD, MSPH
Source: NIAID, NIH - U54-AI-065357
Amount: $434,404
Term: 2005 - 2009
Epidemiology and Pathogenesis of Novel Coronaviruses
Principal Investigator: Samuel R. Dominguez, MD, PhD
Source: TCH Research Institute
Amount: $30,000/yr
Term: 2007 - 2008
Epidemiology and Pathogenesis of Novel Coronaviruses
Principal Investigator: Samuel R. Dominguez, MD, PhD
Consultant: Mark J. Abzug, MD
Source: NIAID, NIH - 1K08AI073525-01A1
Amount: $122,500/yr
Term: 2008 - 2013
Mentored Clinical Scientist Research Career Development Award: Epidemiology and Pathogenesis of Novel Coronaviruses
Principal Investigator: Samuel R. Dominguez, MD, PhD
Source: NIAID, NIH - 1 K08 AI073525-01A1
Amount: $132,220/yr
Term: 2008 - 2013
Pediatric Infectious Disease Society Fellowship Award: Virus Entry and Clinical Significance of the Newly Discovered Human Coronaviruses
Principal Investigator: Samuel R. Dominguez, MD, PhD
Source: Roche Laboratories - CoV-NL63
Amount: $30,000/yr
Term: 2005 - 2007
Specialized Biodefense Training Clinical/Translational: Epidemiology and Characterization of Novel Rocky Mountain Bat Coronaviruses
Principal Investigator: Samuel R. Dominguez, MD, PhD
Source: NIAID, NIH - U54-AIO65367
Amount: $117,170/yr
Term: 2007 - 2008
Phase III Open-label, Nonrandomized International Multicenter Trial to Evaluate Efficacy and Safety of Cardiolite Myocardial Perfusion and Imaging in Pediatric Subjects with Kawasaki Disease
Principal Investigator: Mary P. Glodé, MD
Source: Bristol-Myers Squibb
Amount: Per patient enrolled
Term: 2006 - 2016
Atopic Dermatitis and Vaccinia Immunization Network
Principal Investigator: Myron J. Levin, MD
Source: National Jewish Health, NIAID, NIH - HHSN266200400029C
Amount: $105,092
Term: 2004 - 2008
A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of bD-Alum/MPL Vaccine in the Prevention of Genital Herpes Diseases in Young Women Who are HSV-1 and -2 Seronegative
Principal Investigator: Myron J. Levin, MD
Source: St. Louis University/GlaxoSmithKline, NIAID, NIH - N01-AI-45250
Amount: $1,942,420
Term: 2002 - 2011
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)
Principal Investigator: Myron J. Levin, MD
Source: Social and Scientific Systems (SSS), NIAID, NIH - BRS-Q-06-00116-T002
Amount: $109,916
Term: 2006 - 2013
International Pediatric and Perinatal HIV Studies Network
Principal Investigator: Myron J. Levin, MD
Co-Principal Investigator: Elizabeth J. McFarland, MD
Co-Investigators: Adriana Weinberg, MD, Mark J. Abzug, MD, Robin E. McEvoy, PhD, Suzanne M. Paul, BSN, FNP-C, and Amy Witte, RN, MSN, FNP-C
Source: Westat, NICHD, NIH - N01-HD-3-3345
Amount: $7,008,031
Term: 2002 - 2007
Monitor Subjects Who Originally Received Herpes Zoster Vaccine to Monitor the Durability of the Vaccine
Principal Investigator: Myron J. Levin, MD
Source: Veteran Administration Connecticut Research & Education Foundation (VACREF), Merck - CSP 403C
Amount: $752,088
Term: 2005 - 2010
A Multicenter, Randomized, Double-Blind Study to Compare the Efficacy and Safety of Patient-Initiated Famiciclovir 1000 mg b.i.d. x 1 day to Valacyclovir 500 mg b.i.d. x 3 Days in Immunocompetent Adults with Recurrent Genital Herpes
Principal Investigator: Myron J. Levin, MD
Source: Novartis AG - CFAM810A-A2308
Amount: $94,544
Term: 2006 - 2010
NICHD International and Domestic Pediatric and Maternal HIV Studies Coordinating Center
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Mark J. Abzug, MD
Source: Westat, NICHD, NIH - N01-DK-8-0001
Amount: $1,312,107
Term: 2007 - 2012
NICHD International and Domestic Pediatric and Maternal HIV Studies Coordinating Center
Principal Investigator: Myron J. Levin, MD
Co-Principal Investigator: Elizabeth J. McFarland, MD
Co-Investigators: Adriana Weinberg, MD, Mark J. Abzug, MD, Emily A. Barr, CPNP, CNM, Robin E. McEvoy, PhD, Suzanne M. Paul, BSN, FNP-C, and Amy Witte, RN, MSN, FNP-C
Source: Westat, NICHD, NIDDK, NIH - N01-DK-8-0001
Amount: $7,315,975
Term 2007 - 2012
A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of V21/Heat-Treated Varicella-Zoster Virus (ZVZ) Vaccine in Immumncompromised Adults
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories, Merck & Co., Inc.
Amount: $131,784
Term: 2007 - 2009
A Phase I/II, Double-Blind, Randomized, Controlled, Dose-Range Study to Assess the Safety/Immunogenicity of an HPV-16/18/31/45 VLP/AS04 Vaccine when Administered Intramuscularly
Principal Investigator: Myron J. Levin, MD
Source: GlaxoSmithKline - 102115
Amount: $82,550
Term: 2005 - 2009
A Phase II, Dose-Finding Study with ASP2151 in Subjects with Recurrent Episodes of Genital Herpes
Principal Investigator: Myron J. Levin, MD
Source: Astellas Pharma U.S., Inc. - 200705-280
Amount: $225,321
Term: 2007 - 2011
A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety, and Tolerability of ZOSTAVAX in Subjects 50 to 59 Years of Age, V211-022
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories, Merck & Co., Inc.
Amount: $175,015
Term: 2007 - 2010
A Phase III Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Subjects with a History of Herpes Zoster
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories, Merck & Co., Inc. - V211-014
Amount: $16,198
Term: 2006 - 2009
A Phase III, Double-Blind, Randomized, Controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of Glaxo-Smith Kline Biologicals’ HPV-26/28 L1/AS04 Vaccine Administered Intramuscularly
Principal Investigator: Myron J. Levin, MD
Source: GlaxoSmithKline - 104820
Amount: $66,750
Term: 2006 - 2009
A Phase IIIB, Observer-Blind, Randomized, Multicenter Study with Two Parallel Groups to Compare the Immunogenicity of GSK Biologicals HPV-16/18 L1/AS04 Versus Merck’s Gardasil(R) Vaccine when Administered Intramuscularly According to a 3-Dose Schedule in Healthy Adult Females 18-45 Years of Age
Principal Investigator: Myron J. Levin, MD
Source: GlaxoSmithKline - HPV108933/010
Amount: $86,813
Term: 2007 - 2010
A Randomized, Double-Blind, Active-Controlled, Vehicle-Controlled, Subject-Initiated Study Comparing Efficacy and Safety of ME-609 Versus Acyclovir Cream for Treatment of Recurrent Herpes Simplex Labialis
Principal Investigator: Myron J. Levin, MD
Source: Medivir - ME 609
Amount: $86,730
Term: 2006 - 2009
Retrospective Study That Would Evaluate Asthmatic Children Who Had Already Received Varivax® in the Past
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories, Merck & Co., Inc.
Amount: $69,000
Term: 2003 - 2006
Ryan White Part D HIV Program for Children, Youth, Women, and Families
Principal Investigator: Myron J. Levin, MD
Co-Principal Investigator: Elizabeth J. McFarland, MD
Investigator: Adriana Weinberg, MD
Source: Maternal and Child Health Bureau, HRSA, HHS, - H12HA00070
Amount: $885,272/yr
Term: 2004 - 2007
Ryan White Part D HIV Program for Children, Youth, Women, and Families
Principal Investigator: Myron J. Levin, MD
Co-Principal Investigator: Elizabeth J. McFarland, MD
Investigator: Adriana Weinberg, MD
Source: Maternal and Child Health Bureau, HRSA, HHS - H12HA00070
Amount: $936,325/yr
Term: 2007 - 2012
University of Colorado Center for AIDS Research
Principal Investigator: Thomas Campbell, MD
Co-Principal Investigator: Myron J. Levin, MD
Source: NIAID, NIH - P30 AI054907
Amount: $7,946,900
Term: 2003 - 2008
Comprehensive Resources and Counseling Services for People with HIV
Principal Investigator: Elizabeth J. McFarland, MD
Source: Colorado Department of Public Health and Environment
Amount: $63,074/yr
Term: 2007 - 2009
Evaluation of Programmed Cell Death-1 (PD-1) Expression and Multifunctional HIV-Specific T Lymphocytes in Infants and Children with HIV Infection
Principal Investigator: Elizabeth J. McFarland, MD
Source: Colorado Center for AIDS Research (CFAR) Developmental Projects
Amount: $25,000/yr
Term: 2007 - 2009
Implementation of Rapid HIV Testing at Denver Metro Labor and Delivery Sites
Principal Investigator: Elizabeth J. McFarland, MD
Source: Colorado Department of Public Health and Environment
Amount: $100,231
Term: 2007 - 2009
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)
Principal Investigator: Elizabeth J. McFarland, MD
Source: Social and Scientific Systems (SSS), NIAID, NIH - BRS-Q-06-00116-T001
Amount: $71,381
Term: 2006 - 2013
Pediatric HIV/AIDS Cohort Study (AMP Study)
Principal Investigator: Elizabeth J. McFarland, MD
Source: NICHD, NIH, Harvard - U01-HD052102
Amount: $390,000
Term: 2008 - 2010
Pediatric HIV/AIDS Cohort Study (PHACS) Clinical Site (SMARTT Study)
Principal Investigator: Elizabeth J. McFarland, MD
Co-Investigators: Emily A. Barr, CPNP, CNM, and Robin E. McEvoy, PhD
Source: NICHD, NIH, Harvard - U01-HD052102
Amount: $1,150,000
Term: 2006 - 2010
Ryan White Part A: Funds for HIV Care: Outpatient Ambulatory Medical Care and Pharmaceutical Assistance and Mental Health
Principal Investigator: Elizabeth J. McFarland, MD
Source: Mayor's Office of HIV Resources, HRSA, Ryan White Part A
Amount: $236,794
Term: 2008 - 2009
Ryan White Part B: First Care/Retention in Care
Principal Investigator: Elizabeth J. McFarland, MD
Source: Colorado Department of Public Health and Environment
Amount: $84,000
Term: 2007 - 2009
Ryan White Part B: HIV Supplemental Funding for Medical Care and Behavioral Health and Psychosocial Support
Principal Investigator: Elizabeth J. McFarland, MD
Source: Colorado Department of Public Health and Environment
Amount: $109,439
Term: 2009 - 2010
Ryan White Title I Funds for HIV Care: Primary Health Care and Drug Reimbursement
Principal Investigator: Elizabeth J. McFarland, MD
Source: Mayor's Office of HIV Resources, HRSA Ryan White Title 1
Amount: $274,347
Term: 2006 - 2008
Center for AIDS Research Pharmacy Supplement
Principal Investigator: Courtney Fletcher, PharmD
Co-Investigator: Elizabeth J. McFarland, MD
Source: NIAID, NIH - 5P30 AI054907-04
Amount: $350,002
Term: 2004 - 2007
Impact of Exclusive vs. Mixed Breast Feeding on Susceptibility of Infants to HIV Infection
Principal Investigator: Edward Janoff, MD
Co-Investigator: Elizabeth J. McFarland, MD
Source: Elizabeth Glaser Pediatric AIDS Foundation
Amount: $200,000
Term: 2008 - 2010
Idiopathic Thrombocytopenic Purpura (ITP) After Live Virus and Influenza Vaccines: A Multicenter Retrospective Cohort Study
Principal Investigator: Jason Glanz, PhD
Co-Principal Investigator: Sean O’Leary, MD
Source: FDA
Amount: $1,041,000
Term: 2008 - 2010
Construction and Phenotypic Assessment of Mycobacterial Phospholipase A Deletion Mutants
Principal Investigator: Sarah K. Parker, MD
Source: Potts Memorial Foundation - 200709-039
Amount: $32,000
Term: 2007 - 2008
Construction and Phenotypic Assessment of Mycobacterial Phospholipase A Deletion Mutants
Principal Investigator: Sarah K. Parker, MD
Source: TCH Research Institute
Amount: $70,000/yr
Term: 2007 - 2009
Investigation of Mycobacterium Tuberculosis Phospholipase A Cell Wall Activity
Principal Investigator: Sarah K. Parker, MD
Source: American Lung Association
Amount: $40,000/yr
Term: 2008 - 2010
Phospholipases in the Pathogenesis of Mycobacterium Tuberculosis
Principal Investigator: Sarah K. Parker, MD
Source: NIAID, NIH - 5 K08 AI050646-05
Amount: $125,280
Term: 2002 - 2008
Determination of Sensitive Methods for Detecting Respiratory Virus Infections in Respiratory Tract Secretions
Principal Investigator: Eric A. Simões, MB, BS, DCH, MD
Source: Bill & Melinda Gates Foundation - 2581081
Amount: $265,977
Term: 2008 - 2010
Pneumo-Accelerated Development and Introduction Plan (ADIP)
Principal Investigator: Eric A. Simões, MB, BS, DCH, MD
Source: Johns Hopkins University - 2580754
Amount: $25,000
Term: 2005 - 2009
Zoonotic Avian Influenza: The Human-Animal Interface in the U.S. and Asia
Co-Principal Investigator: Eric A. Simões, MB, BS, DCH, MD
Source: CDC - 2580805
Amount: $485,000/yr
Term: 2006 - 2009
Atopic Dermatitis and Vaccinia Network (ADVN) Biomarker Registry Study
Principal Investigator: Adriana Weinberg, MD
Source: NIAID, NIH - N01-AI-40029
Amount: $80,711/yr
Term: 2007 - 2009
Critical Aspects of Successful Management of HIV Infection During Pregnancy
Principal Investigator: Adriana Weinberg, MD
Source: Abbott Laboratories - IIS-USAV-05-020
Amount: $35,973
Term: 2005 - 2009
Dendritic Cell Co-Infection with HIV and CMV
Principal Investigator: Adriana Weinberg, MD
Source: NIAID, NIH, and Colorado Center for AIDS Research - 5P30 AI054907
Amount: $25,000/yr
Term: 2007 - 2008
HSV Susceptibility to ASP2151
Principal Investigator: Adriana Weinberg, MD
Source: Astellas Pharma US, Inc.
Amount: $782,135
Term: 2007 - 2009
Incidence of hMPV in Lung Transplant Recipients
Principal Investigator: Adriana Weinberg, MD
Source: MedImmune, Inc. - SYN092-04d
Amount: $39,279
Term: 2005 - 2009
Influenza A and B Respiratory Specimens Acquisition
Principal Investigator: Adriana Weinberg, MD
Source: BD Diagnostics, Inc.
Amount: $40,413
Term: 2007 - 2010
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT):
Immunology Core Laboratory
Principal Investigator: Adriana Weinberg, MD
Co-Principal Investigator: Elizabeth J. McFarland, MD
Source: NICHD, NIH - N01-HD-33162
Amount: $300,000/yr
Term: 2007 - 2012
Kinetics of Viral Shedding and Immunologic Responses to the Cold-Adapted Influenza Vaccine
Principal Investigator: Adriana Weinberg, MD
Source: MedImmune, Inc. - CAIV-T
Amount: $135,645
Term: 2006 - 2009
Mechanisms of Protection of Varicella-Zoster Virus Infection Against Glioblastoma
Principal Investigator: Adriana Weinberg, MD
Source: National Cancer Institute, NIH - P30 CA046934
Amount: $20,000/yr
Term: 2008 - 2009
Reconstitution of Protective CMV Immunity and Immune Regulation After HAART
Principal Investigator: Adriana Weinberg, MD
Source: NIAID, NIH - 1R21AI073121-01A2
Amount: $125,000/yr
Term: 2007 - 2009
RSV and PIV Immunology Pilot
Principal Investigator: Adriana Weinberg, MD
Source: MedImmune, Inc.
Amount: $187,562/yr
Term: 2005 - 2009
Type 1 Diabetes TrialNet Study
Principal Investigator: Adriana Weinberg, MD
Source: NIDDK, NIH - U01 DK61055
Amount: $385,750/yr
Term: 2003 - 2012
Epidemiology of Adult Glioma
Principal Investigator: Margaret Wrensch, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Cancer Institute, NIH - R01 CA52689
Amount: $14,009/yr
Term: 1997 - 2012